By MacKay Jimeson

Some of the most exciting advances in science and medicine are happening in Alzheimer’s, a disease that is one of the greatest epidemics of this generation. Eli Lilly announced promising results last week for experimental amyloid-targeting drug donanemab. These clinical trial results showed that the drug can slow cognitive and functional decline for people with early-stage Alzheimer’s disease.

While not yet approved by the U.S. Food & Drug Administration (FDA), the clinical evidence suggests that Lilly will join Eiasi and Biogen as important new medicines for Alzheimer’s patients that can significantly slow memory-robbing disease.

Continue Reading at